AR and prostate carcinoma: However, advancements in the field of genetics have unraveled responsive prostate cancer sites besides the AR (Ren, Chen, et al. 2023; Ren, Li, et al. 2023), such as poly (ADP‐ribose) polymerase, which is a target for PAPP inhibitor drugs for DNA repair abnormalities, and PD1, whose blockage can be employed in incompatible repair insufficiency (de Bono et al. 2020).